Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 10/20 | 0.53 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20009391 | 0.89 | MBOAT4 (0.50) | MBOAT4TLR8FAAHKDM4EPKM | |
| SCHEMBL19991495 | 0.85 | MBOAT4 (0.65) | MBOAT4TLR8FAAHKDM4EPKM | |
| SCHEMBL16699034 | 0.85 | MBOAT4 (0.63) | MBOAT4FAAHKDM4EPKMGLS | |
| SCHEMBL19971825 | 0.84 | MBOAT4 (0.67) | MBOAT4 | |
| SCHEMBL19979151 | 0.81 | MBOAT4 (0.63) | MBOAT4 | |
| SCHEMBL16699845 | 0.81 | MBOAT4 (0.49) | MBOAT4FAAHKDM4EPKMGLS | |
| SCHEMBL28406440 | 0.81 | MBOAT4 (0.59) | MBOAT4FAAHKDM4EPKMGLS | |
| SCHEMBL28406437 | 0.81 | MBOAT4 (0.59) | MBOAT4FAAHKDM4EPKMGLS | |
| SCHEMBL18166117 | 0.81 | MBOAT4 (0.59) | MBOAT4FAAHKDM4EPKMGLS | |
| Hydrochloric Acid SCHEMBL19971782 | 0.80 | MBOAT4 (0.62) | MBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107454898-B | Ghrelin O-acyltransferase inhibitors | 伊莱利利公司 | 2020-05-05 | — | — | CN | disclosed |
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-22 | — | — | US | disclosed |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-22 | — | — | US | disclosed |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-22 | — | — | US | disclosed |
| EP-3283474-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | Eli Lilly and Company (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016168225-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168225-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | MBOAT4, GIPR, PLAAT2 | MBOAT4 1/4885TLR8 4782/4885FAAH 655/4885 |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | MBOAT4, GIPR, PLAAT2 | MBOAT4 1/4885TLR8 4782/4885FAAH 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.